Companies / BOC Sciences / Lampalizumab
BOC Sciences

Lampalizumab | BOC Sciences

Lampalizumab is a humanized monoclonal antibody that targets complement factor D (CFD). In 2017, age-related macular degeneration (AMD) blockbuster-to-be has failed a phase 3 trial.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.